healthcareЗдравоохранение. HealthcareHealthcare1027-7218Republican Scientific and Practical Center for Medical Technologies, Informatization, Management and Health Economicshealthcare-171Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEВлияние пандемии COVID-19 на результаты хирургического лечения пациентов со злокачественными опухолями легкихThe impact of the COVID-19 pandemic on the results of surgical treatment of patients with lung malignanciesКороткевичП. Е.KorotkevichP. E.

Короткевич Павел Евгеньевич - к. м. н., врач, онколог-хирург, зав. онкологическим торакальным отделением

агр. гор. Лесной, 1, 223040, Минский р-н, БеларусьСл. тел. +375 29 181-87-40

ПивоварчикС. Н.PivovarchikS. N.

Минск, Беларусь

АбражейчикО. Ю.AbrazhejchikO. Ju.

Минск, Беларусь

ВасилевичС. Н.VasilevichS. N.

Минск, Беларусь

РНПЦ онкологии и медицинской радиологии им. Н. Н. АлександроваBelarus2023270920250124852Copyright © Короткевич П.Е., Пивоварчик С.Н., Абражейчик О.Ю., Василевич С.Н., 20252025Короткевич П.Е., Пивоварчик С.Н., Абражейчик О.Ю., Василевич С.Н.Korotkevich P.E., Pivovarchik S.N., Abrazhejchik O.J., Vasilevich S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://healthcare.ejournal.by/jour/article/view/171

Цель исследования. Изучить влияние пандемии COVID-19 на результаты хирургического лечения пациентов со злокачественными опухолями легких.Материал и методы. Материалом для исследования послужили наблюдения за 1187 пациентами со злокачественными опухолями легких, которым проведено радикальное хирургическое лечение в объеме анатомической резекции легкого (лобэктомия, билобэктомия, пневмонэктомия, в том числе видеоассистированные и комбинированные) на базе онкологического торакального отделения РНПЦ онкологии и медицинской радиологии им. Н. Н. Александрова с 01.01.2018 по 31.12.2021 г. Пациенты были разделены на 2 группы: оперированные в 2018 2019 гг. (до начала пандемии) и в 2020-2021 гг. (в период пандемии). Основными оцениваемыми показателями результатов лечения выбраны 30- и 90-дневная летальность, 1-летняя общая выживаемость.Результаты. Показатели 30- и 90-дневной летальности в период 2018 -2019 гг. и 2020 2021 гг. составили 2,8 и 3,8 % (р=0,3061) и 4,4 и 6,4 % (р=0,1197) соответственно. Статистически значимых межарупповых различий в показателях общей выживаемости не выявлено (р=0,3725).Заключение. Пандемия COVID-19 не привела к статистически значимому ухудшению результатов хирургического лечения пациентов со злокачественными опухолями легких в сравнении с допандемийным периодом.

Objective. To study the effect of COVID-19 pandemic on the results of surgical treatment of patients with malignant lung tumors.Materials and methods. The material for the study included observations of 1187 patients with malignant lung tumors who underwent radical surgical treatment in the volume of anatomic lung resection (lobectomy, bilobectomy, pneumonectomy, including video-assisted and combined ones) at the oncologic thoracic department of the Alexandrov Russian Research Center for Oncology and Medical Radiology. The patients were divided into 2 groups: those operated on in 2018 -2019 before pandemic onset and in 2020-2021, i.e. in the pandemic period. The 30- and 90-day mortality rates and 1-year overall survival were chosen as the main outcome measures.Results. The 30- and 90-day mortality rates for 2018 -2019 and 2020-2021 were 2,8 % and 3,8 % (p=0,3061) and 4,4 % and 6,4 % (p=0,1197), respectively. There were no significant intergroup differences in overall survival rates (p=0,3725).Conclusions. The COVID-19 pandemic did not result in a statistically significant worsening of surgical outcomes in patients with malignant lung tumors compared with the pre-pandemic period.

пандемия COVID-19рак легкогохирургическое лечение30-90-дневная летальностьвыживаемостьCOVID-19 pandemicLung CancerSurgery30-90-days mortalitysurvivalReferencesBerzenji L., Vercauteren L., Yogeswaran S. K. et al. Safety and Feasibility of Lung Cancer Surgery under the COVID-19 Circumstance. Cancers. 2022; 14 (5): 1334.Berzenji L., Vercauteren L., Yogeswaran S. K. et al. Safety and Feasibility of Lung Cancer Surgery under the COVID-19 Circumstance. Cancers. 2022; 14 (5): 1334.Dong E., Du H., Gardner L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet. Infectious diseases. 2020: 20 (5): 533 4Dong E., Du H., Gardner L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet. Infectious diseases. 2020: 20 (5): 533 4Richards M., Anderson M., Carter P. et al. The impact of the COVID-19 pandemic on cancercare. Nature cancer. 2022; 1 (6): 565 7.Richards M., Anderson M., Carter P. et al. The impact of the COVID-19 pandemic on cancercare. Nature cancer. 2022; 1 (6): 565 7.Spinelli A., Pellino G. COVID-19 pandemic: Perspectives on an unfolding crisis. The British journal of surgery. 2020; 107 (7): 785Spinelli A., Pellino G. COVID-19 pandemic: Perspectives on an unfolding crisis. The British journal of surgery. 2020; 107 (7): 785Hashim M. J., Alsuwaidi A. R., Khan G. Population Risk Factors for COVID-19 Mortality in 93 Countries. J. epidemiology global health. 2020; 10 (3): 204 -208.Hashim M. J., Alsuwaidi A. R., Khan G. Population Risk Factors for COVID-19 Mortality in 93 Countries. J. epidemiology global health. 2020; 10 (3): 204 -208.Zheng Z., Peng F., Xu B. et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J. infection. 2020; 81 (2): 16 25.Zheng Z., Peng F., Xu B. et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J. infection. 2020; 81 (2): 16 25.Li X., Xu S., Yu M. et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J. allergy and clinical immunology. 2020; 146 (1): 110 8.Li X., Xu S., Yu M. et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J. allergy and clinical immunology. 2020; 146 (1): 110 8.Wang A., Chang S. H., Kim E. J. et al. Dynamic Management of Lung Cancer Care During Surging COVID-19. Frontiers in surgery. 2021; 8: 663 4.Wang A., Chang S. H., Kim E. J. et al. Dynamic Management of Lung Cancer Care During Surging COVID-19. Frontiers in surgery. 2021; 8: 663 4.Lee L. Y., Cazier J. B., Angelis V. et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet (London, England). 2020; 395: 1919 26.Lee L. Y., Cazier J. B., Angelis V. et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet (London, England). 2020; 395: 1919 26.Zhang L., Zhu F., Xie L. et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Annals of oncology: official journal ofthe European Society for Medical Oncology. 2020; 31 (7): 894 901.Zhang L., Zhu F., Xie L. et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Annals of oncology: official journal ofthe European Society for Medical Oncology. 2020; 31 (7): 894 901.Passaro A., Bestvina C., Velez Velez M. et al. Severity of COVID-19 in patients with lung cancer: Evidence and challenges. Journal for immunotherapy of cancer. 2021; 9 (3): 226 68.Passaro A., Bestvina C., Velez Velez M. et al. Severity of COVID-19 in patients with lung cancer: Evidence and challenges. Journal for immunotherapy of cancer. 2021; 9 (3): 226 68.Hom L., Garassino M. COVID-19 in patients with cancer: Managing a pandemic within a pandemic. Nature reviews. Clinical oncology. 2021; 18 (1): 1-2.Hom L., Garassino M. COVID-19 in patients with cancer: Managing a pandemic within a pandemic. Nature reviews. Clinical oncology. 2021; 18 (1): 1-2.Короткевич П. Е., Пивоварчик С. Н., Аброжейчик О. Ю. и др. Влияние COVID-19 на результаты хирургического печения онкологических пациентов с опухолями торакальной локализации. Онколог. журн. 2022; 16 (3 4): 5 10.Korotkevich P. E., Pivovarchik S. N., Abrozhejchik O. Yu. et al. The impact of the COVID-19 on the results of surgical treatment of patients with thoracic malignancies. Onkolog. zhum. 2022; 16 (3 4 34): 5 -10. [(in Russian)]Gabryel P., Zielinska D., Skrzypczak P. et al. Outcomes of lung cancer surgery in patients with COVID-19 history: a single center cohort study. General thoracic and cardiovascular surgery. 2023; 71 (3): 175 81.Gabryel P., Zielinska D., Skrzypczak P. et al. Outcomes of lung cancer surgery in patients with COVID-19 history: a single center cohort study. General thoracic and cardiovascular surgery. 2023; 71 (3): 175 81.Keogh J. A., Chhor J., Begum A. D. et al. Impact of the COVID-19 pandemic on non-small-cell lung cancer pathologic stage and presentation. Canadian journal of surgery. Joumal canadien de chirurgie. 2022; 65(4): 496 503.Keogh J. A., Chhor J., Begum A. D. et al. Impact of the COVID-19 pandemic on non-small-cell lung cancer pathologic stage and presentation. Canadian journal of surgery. Joumal canadien de chirurgie. 2022; 65(4): 496 503.Piwkowski C., Gabryel P., Orlowski T. M. et al. The impact of the COVID-19 pandemic on surgical treatment of lung cancer. Pol. Arch. Intern. Med. 2022; 132 (2): 16191.Piwkowski C., Gabryel P., Orlowski T. M. et al. The impact of the COVID-19 pandemic on surgical treatment of lung cancer. Pol. Arch. Intern. Med. 2022; 132 (2): 16191.Wang L., Wang Y., Cheng X. etal. Impactofcoronavirus disease 2019 on lung cancer patients: A metaanalysis. Transl. Oncol. 2023; 28: 101605.Wang L., Wang Y., Cheng X. etal. Impactofcoronavirus disease 2019 on lung cancer patients: A metaanalysis. Transl. Oncol. 2023; 28: 101605.

The authors declare that there are no conflicts of interest present.